Literature DB >> 26854121

Physical exercise as a treatment for adult and juvenile myositis.

H Alexanderson1,2.   

Abstract

There is growing evidence to support the safety and efficacy of exercise in patients with adult and juvenile idiopathic inflammatory myopathies. Five randomized controlled trials including adult patients with polymyositis and dermatomyositis (DM) and additional open studies have demonstrated reduced impairment and activity limitation as well as improved quality of life. In addition, recent studies have shown reduced disease activity assessed by consensus disease activity measures and reduced expression of genes regulating inflammation and fibrosis. Furthermore, exercise could improve muscle aerobic capacity as shown by increased mitochondrial enzyme activity. These data suggest that intensive aerobic exercise and resistance training could reduce disease activity and inflammation and improve muscle metabolism. Encouraging results have been reported from available open studies including patients with inclusion body myositis (IBM) and juvenile DM, indicating reduced impairment, activity limitation and improved quality of life also in these patients. Larger studies are needed to increase understanding of the effects of exercise in patients with active, recent-onset polymyositis and DM as well as in patients with IBM and juvenile DM.
© 2016 The Association for the Publication of the Journal of Internal Medicine.

Entities:  

Keywords:  aerobic exercise; disease activity; impairment; inflammation; inflammatory myopathies; resistance training

Mesh:

Year:  2016        PMID: 26854121     DOI: 10.1111/joim.12481

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  10 in total

1.  Immunohistochemical and ultrastructural analysis of sporadic inclusion body myositis: a case series.

Authors:  Katarzyna Haczkiewicz; Agata Sebastian; Aleksandra Piotrowska; Maria Misterska-Skóra; Agnieszka Hałoń; Marta Skoczyńska; Maciej Sebastian; Piotr Wiland; Piotr Dzięgiel; Marzenna Podhorska-Okołów
Journal:  Rheumatol Int       Date:  2018-12-08       Impact factor: 2.631

2.  [Sports and exercise therapy in inflammatory rheumatic diseases].

Authors:  Wolfgang Hartung; Philipp Sewerin; Benedikt Ostendorf
Journal:  Z Rheumatol       Date:  2021-03-08       Impact factor: 1.372

Review 3.  Treatment in myositis.

Authors:  Chester V Oddis; Rohit Aggarwal
Journal:  Nat Rev Rheumatol       Date:  2018-03-29       Impact factor: 20.543

Review 4.  Exercise in Myositis.

Authors:  Helene Alexanderson
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-11-23

Review 5.  Current Treatment for Myositis.

Authors:  Simone Barsotti; Ingrid E Lundberg
Journal:  Curr Treatm Opt Rheumatol       Date:  2018-09-15

6.  Feasibility of a blended therapy approach in the treatment of patients with inflammatory myopathies.

Authors:  Pierrette Baschung Pfister; Ruud H Knols; Rob A de Bie; Eling D de Bruin
Journal:  Arch Physiother       Date:  2021-05-27

7.  Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis.

Authors:  Jie Zheng; Yunchen Le; Hua Cao; Dan Wu; Mengya Chen; Shile Chen; Shimin Zhang; Yongheng Chen; Qian Zhao; Ke Xue; Feng Xue; Xiaosong Chen; Min Zhou; Hao Li
Journal:  Clin Rheumatol       Date:  2022-07-01       Impact factor: 3.650

Review 8.  Current Classification and Management of Inflammatory Myopathies.

Authors:  Jens Schmidt
Journal:  J Neuromuscul Dis       Date:  2018

9.  Exercise enhances skeletal muscle regeneration by promoting senescence in fibro-adipogenic progenitors.

Authors:  Yuki Saito; Takako S Chikenji; Takashi Matsumura; Masako Nakano; Mineko Fujimiya
Journal:  Nat Commun       Date:  2020-02-14       Impact factor: 14.919

10.  Factors Associated With Treatment Response in Patients With Idiopathic Inflammatory Myopathies: A Registry-Based Study.

Authors:  Fabricio Espinosa-Ortega; Marie Holmqvist; Maryam Dastmalchi; Ingrid E Lundberg; Helene Alexanderson
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-02-12       Impact factor: 5.178

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.